Bullish & Foolish
--
--

Is Pluri going out of business?

Loading the full analysis
Reading the filings

PLURI INC. (PLUR) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

PLURI INC. (PLUR) scores 12 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Quality score 12/100
Rating Distressed / Caution
Sector Biotech/Pharma
Market cap $16.8M
Last close $1.36
Revenue growth (YoY) 4.4%
FCF margin (TTM) -3561.5%
Dividend yield 0.0%

Leading signal: Shares dilution YoY: 61.01% (YoY)

Five questions, kept separate

Survival - Critical
1-2 mo of estimated runway from 2026-03-31, based on $3.4M of cash and short-term investments against $38.4M of annual burn. Adjusted shares outstanding increased 61.0% over the comparison year.
Business quality - Pre-commercial
Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.
Trajectory - Clinical progress unavailable
Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.
Valuation - Extreme expectations
-17.6% net-cash backing support an extreme expectations pre-commercial Valuation assessment.
Event risk - Evidence unavailable
No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

  • Shares dilution YoY: 61.01% (YoY)
  • Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)
  • FCF margin: -3561.54%
  • Cash Runway (years): 0.09y
  • Revenue CAGR (3Y): 78.73%
  • Return on Assets: -98.01%
  • Cash Burn Deceleration: -66.81% QoQ improvement (Worsening)
  • Price / Sales: 14.8x (see Valuation)
  • Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-05-14.

Price as of 2026-09-07.

Headline score detail

Source coverage and limitations
--
Reference Links